Bharat Biotech
https://www.bharatbiotech.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Bharat Biotech
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet
BMS’ Boerner Bets On AI-Driven R&D In India, Points To Potential For MS, Lupus Drugs
Bristol Myers Squibb CEO Christopher Boerner is looking to India to house the the company’s largest R&D site outside of the US, channeling the country's IT expertise to expand its AI-driven small-molecule research. He also wants to bring its drugs to treat multiple sclerosis and Lupus to India.
Zydus MD On Quest For Novel ADCs, Antibodies Amid Shifting Modalities
Zydus is developing a novel ADC, one of the most challenging but rewarding treatment modalities today as others in the class like Kadcyla and Enhertu prove. The Indian firm's managing director spoke to Scrip about R&D efforts, recent policy moves and gains from making the world’s first approved recombinant plasmid DNA vaccine.
Merck Life Execs On APAC Firms' mRNA Tech Readiness, Start-Ups And AI
Merck Life Science’s top executives in India tell Scrip how they are helping biologics companies in APAC on their mRNA therapy journey. In the wide-ranging discussion, use of AI, the startup environment for biotechs and the changing face of manufacturing in India also came up.
Company Information
- Industry
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Drug Discovery Tools
- Other Names / Subsidiaries
-
- Chiron Behring Vaccines Pvt Ltd
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice